New Users Registration  |  Useful Links  |  FAQ  |  Site Map 
 
Go Search

 

Skip Navigation LinksHealth Xchange > News
  News  
  Categories  
     
  Chronology  
 
  2013 2014   Dec 2014 | Nov 2014 | Oct 2014 | Sep 2014 | Aug 2014 | Jul 2014 | Jun 2014 | May 2014 | Apr 2014 | Mar 2014 | Feb 2014 | Jan 2014 |
  2013   Dec 2013 | Nov 2013 | Oct 2013 | Sep 2013 | Aug 2013 | Jul 2013 | Jun 2013 | May 2013 | Apr 2013 | Mar 2013 | Feb 2013 | Jan 2013 |
  2012   Dec 2012 | Nov 2012 | Oct 2012 | Sep 2012 | Aug 2012 | Jul 2012Jun 2012May 2012Apr 2012Mar 2012 | Feb 2012 | Jan 2012 |
  2011   Dec 2011Nov 2011Oct 2011 | Sep 2011 | Aug 2011Jul 2011Jun 2011 | May 2011 | Apr 2011 | Mar 2011 | Feb 2011 | Jan 2011 |
  2010   Dec 2010 | Nov 2010 | Oct 2010 | Sep 2010 | Aug 2010 | Jul 2010 | Jun 2010 | May 2010 | Apr 2010 | Mar 2010 | Feb 2010 | Jan 2010 |
  2009   Dec 2009 | Nov 2009 | Oct 2009 | Sep 2009 | Aug 2009 |
 
     
  Topic  
 
  Health Policy and Announcements | Diseases and Outbreaks
  Medical Research | New Treatments and Technology
   
 
     
  RSS  
 
  Singapore   SingHealth | Health Promotion Board | Ministry of Health | Asiaone
  International   World Health Organization | Centre for Disease Control and Prevention (US)
       
 
     
  News Article  
 

Zeroing in on enzyme to battle cancer

 
  Saturday, 07 l 08 l 2010 Source:  The Straits Times   
By: Grace Chua
     
 

A*Star researcher first identified and now aims to stop PRL-3, which promotes cancer growth

FOR more than 10 years, a mild-mannered, bespectacled researcher in Singapore has been in hot pursuit of an enzyme involved in the rapid growth of deadly cancers.

enzyme to battle cancerDr Zeng Qi, from the Agency for Science, Technology and Research’s (A*Star) Institute of Molecular and Cell Biology (IMCB), first identified the enzyme PRL-3 in 1998, in cells that were “going crazy, zhang ya wu zhao (Chinese for ‘baring teeth and brandishing claws’)”.

As it turned out, PRL-3, which stands for “phosphatase of regenerating liver-3”, is key to metastasis, a process in which aggressive lung, pancreatic and other cancers grow very fast and spread to other parts of the body. And it is commonly overproduced in human cancers, making it an ideal target for cancer treatment.

Since then, Dr Zeng, 50, has made it her mission to explore the enzyme’s function and stop it in its tracks.

Last year, her team was awarded a $3 million flagship grant for its research to make human antibodies to combat the cancer-growth enzyme, conduct antibody safety tests in animals, and take the antibodies through to early clinical trials. The grant, from A*Star’s commercialisation arm Exploit Technologies, is meant to shepherd the work from laboratory to industry.

Last month, Dr Zeng’s team published a paper in the journal Cancer Cell, offering conclusive proof that a particular protein, PCBP1, suppresses the translation of the PRL-3 gene and thus cuts down the enzyme’s production.

The finding is a simple, small piece of work. But this is how Dr Zeng operates, by chipping away bit by bit at a large problem. As a young researcher at IMCB, she made a name for herself in 1991 by helping to breed the world’s first genetically engineered rats for human diabetes studies. Later, she switched to cancer research as it delivered faster results.

Breeding transgenic mice requires fertilising the eggs, waiting for the animals to be born, and studying them in detail, and can take years, Dr Zeng explained. In comparison, cancer experiments take a few weeks to a few months.

“We make cancer metastasise in mice and try to rescue them using different treatments,” she said, in a kind of “mouse clinic”.

Already, her research has identified specific antibodies that block PRL-3-associated cancers in mice, and it is now up to A*Star to get them into clinical use. The passion for research runs in Dr Zeng’s family: her husband Heng Wanjin, 50, whom she met at Xiamen University in China’s Fujian province, is deputy director of IMCB. The couple have worked in Singapore for 20 years, and been Singapore citizens for 18 of those years.

Their elder son, 21, who was born in the United States while the couple were in graduate school, is now studying at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Ohio.

She said: “He said to me, ‘Mummy, if your cancer drugs work, we should set up a charity for children’s leukaemia’.”

Dr Zeng, whose younger son is in Raffles Institution, said: “If you are doing some research, at the end of the day, you must feel that your research can help people. It’s not just to publish papers and get promotions.”

Discovering new cancer signposts

BESIDES Dr Zeng Qi’s paper on the PRL-3 enzyme, two other cancer-related projects out of the Agency for Science, Technology and Research were published recently in top journals.

The Institute of Molecular and Cell Biology’s Dr Vinay Tergaonkar and colleagues from Singapore and the US found that a protein called Rap1 is an important marker of breast cancer.

They also found that levels of Rap1 and where they are found could serve as markers of various diseases, and that Rap1 may be essential to keeping breast cancer cells alive, meaning it would make a good target for cancer treatment.

Their research was published online last month in Nature Cell Biology.

In a separate project, the Institute of Medical Biology’s Dr Francoise Thierry and colleagues from Singapore and China studied types of human papillomaviruses (HPV) associated with cervical cancer.

Cervical cancer is the fifth most deadly cancer in women worldwide, according to World Health Organisation statistics, and it affects about 16 out of every 100,000 women a year.

The scientists found that a protein called HPV16 E2 can be detected at a very early stage of HPV infection, which could lead to earlier treatment for HPV and cervical cancer.

Their research was published in the journal Cancer Research in June.

     
  Ask the Specialists - Free Doctor Q&A
(Now - 31st Jul)
 
    Stress and Anxiety
If you have questions on stress and anxiety, take this opportunity to ask our specialist today.
 
    Previous Q&As
Check out our archive for all our previous doctor's Q&As!
*Latest Update: About LASIK
 
e-Appointment Online
Health Buddy App